CYTOKINETICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CYTOKINETICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $13.37M | Mar 5, 2018 |
| FY2017 | Dec 31, 2016 | $106.41M | Mar 5, 2018 |
| FY2017 | Dec 31, 2015 | $28.66M | Mar 5, 2018 |
| FY2016 | Dec 31, 2014 | $46.94M | Mar 6, 2017 |
| FY2015 | Dec 31, 2013 | $30.65M | Mar 3, 2016 |
| FY2014 | Dec 31, 2012 | $7.56M | Mar 6, 2015 |
| FY2013 | Dec 31, 2011 | $4.00M | Mar 7, 2014 |
| FY2012 | Dec 31, 2010 | $2.58M | Mar 15, 2013 |
| FY2011 | Dec 31, 2009 | $81.54M | Mar 13, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $7.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $94.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $70.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $55.83M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $26.87M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $31.50M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $13.37M | Mar 7, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($18.0K) | Mar 5, 2018 |
| FY2017 | Sep 30, 2017 | $6.18M | Mar 5, 2018 |
| FY2017 | Jun 30, 2017 | $3.05M | Mar 5, 2018 |
| FY2017 | Mar 31, 2017 | $4.15M | Mar 5, 2018 |
| FY2017 | Dec 31, 2016 | $33.14M | Mar 5, 2018 |
| FY2017 | Sep 30, 2016 | $59.05M | Mar 5, 2018 |
| FY2017 | Jun 30, 2016 | $5.80M | Mar 5, 2018 |
| FY2017 | Mar 31, 2016 | $8.42M | Mar 5, 2018 |
| FY2016 | Dec 31, 2015 | $9.76M | Mar 6, 2017 |
| FY2016 | Sep 30, 2015 | $7.95M | Mar 6, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($784.96M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($589.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($526.24M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($388.96M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($215.31M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($127.29M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($121.69M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($106.29M) | Feb 26, 2021 |
| FY2017 | Dec 31, 2017 | ($40.48M) | Mar 5, 2018 |
| FY2017 | Sep 30, 2017 | ($32.36M) | Mar 5, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($612.26M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($536.25M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($496.21M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($324.20M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($186.31M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($93.94M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($98.87M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($88.92M) | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | ($113.40M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $18.69M | Mar 5, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $339.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $330.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $240.81M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $159.94M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $96.95M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $86.13M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $89.14M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $90.30M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $59.90M | Mar 5, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($510.01M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($395.89M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($414.33M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($299.52M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($142.52M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $8.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($90.91M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($101.22M) | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | ($101.76M) | Mar 7, 2019 |
| FY2013 | Dec 31, 2013 | ($7.72M) | Mar 7, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.42M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $11.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $48.87M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $11.05M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $2.62M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $889.0K | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $2.88M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $1.60M | Mar 5, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.42B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $824.32M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.01B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $841.32M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $533.80M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $289.81M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $211.18M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $294.81M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $170.14M | Mar 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.08B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.21B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.12B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $597.46M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $420.42M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $300.75M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $185.24M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $184.97M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $75.78M | Mar 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($659.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($135.37M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($386.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | ($107.90M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $243.86M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $113.38M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | ($10.94M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $25.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $109.84M | Feb 26, 2021 |
| FY2018 | Dec 31, 2016 | $94.36M | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.49B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.70B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.11B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.59B) | Feb 28, 2024 |
| FY2022 | Jan 1, 2022 | ($1.20B) | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | ($1.21B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($992.31M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($865.02M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($743.32M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($646.08M) | Mar 7, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $94.86M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $113.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $65.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $112.67M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $82.99M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $36.43M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $42.26M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $125.21M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $66.87M | Mar 5, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $619.52M | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $639.27M | Feb 28, 2024 |
| FY2022 | Dec 31, 2022 | $649.56M | Mar 1, 2023 |
| FY2018 | Dec 31, 2018 | $42.41M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $31.78M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $29.88M | Mar 5, 2018 |
| FY2016 | Dec 31, 2015 | $14.64M | Mar 6, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2017 | Dec 31, 2017 | (2) | Mar 5, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 5, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 5, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Mar 5, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2017 | Dec 31, 2017 | (2) | Mar 5, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 5, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 5, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Mar 5, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 122.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 118.21M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 101.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 94.83M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 84.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 71.02M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 59.17M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 54.72M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 53.96M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 40.65M | Mar 5, 2018 |